BioSpace News Archive

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020 at 9:30 a.m. Eastern Time in New York, NY.

Deciphera Pharmaceuticals, Inc. announced the commencement of a registered underwritten public offering of $250.0 million in shares of its common stock.

AVEO Oncology (NASDAQ: AVEO) today announced the publication of results from a monotherapy trial of tivozanib, the Company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), in patients with advanced, inoperable hepatocellular carcinoma (HCC) in the British Journal of Cancer.

AmorChem II is proud to announce the financing of a collaboration centered around c-Myc, a proto-oncogene implicated in over 50% of all human cancers.

Johnson & Johnson will participate in the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, Feb. 26th, at Lotte New York Palace, NY. Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices will represent the Company in a session scheduled at 2:00 p.m.

SAN DIEGO, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (“Cidara”) today announced the closing of its previously announced rights offering (the “Rights Offering”). At the closing, Cidara sold and issued an aggregate of 6,639,307 shares of its common stock (the “Common Stock”) and an aggregate of 531,288 shares of its Series X convertible preferred stock (“Series X Preferred Stock”), pursuant to the exercise of subscription rights in the Rights Offering from its ex

Survey by Travel Leaders Network assesses impact of coronavirus on leisure travel bookings

Guardant Health, Inc. announced the company will be participating in two upcoming investor conferences.

Acerus Pharmaceuticals Corporation announced that it has entered into agreements with First Generation Capital, Inc. in respect of an equity financing and debt-to-equity conversion by First Generation and with SWK Funding LLC in respect of an amendment to the Company’s existing credit facility with SWK.

POXEL SA announced that new preclinical proof-of-concept results for PXL770 for the treatment of NASH were reported in an oral presentation during the 3rd Annual Global NASH Congress held in London, February 10-11, 2020.